We studied the efficacy and tolerability of glycosaminoglycan polysulfuric acid (GAGPS) in 80 patients with osteoarthritis (OA) of the knee. Patients received two series of five intra-articular injections, at l-week intervals, of 25 mg (0.5 ml) GAGPS into the knee in a double-blind, parallel, randomized, placebo-controlled trial. There was an immediate decrease in pain after the injections of 43% with GAGPS and 33% with placebo (P = 0.047) (Jezek pain index). Pain relief of GAGPS vs placebo was not different at other intervals (10, 14, 22, 26 weeks after start of treatment). At 6 weeks the Lequesne index decreased 20% after GAGPS and 9% after placebo (P = 0.17). At 10 weeks the Lequesne index decreased 24% after GAGPS and 13~/o after placebo (P = 0.20). The decrease in Lequesne index at 14 weeks was 31% after GAGPS and 15% after placebo (P = 0.06). The other measured parameters tended to be more favorably influenced by GAGPS than placebo. GAGPS was well tolerated, with associated mild adverse reactions in 8% of cases. GAGPS may have a role as a symptomatic slow acting drug for OA. Further study appears appropriate.
Introduction
OSTEOARTHRITIS (OA) of the knee is one of the most common diseases of an older population, the prevalence being as high as 30% in a population ~>63 years of age [1] . Disturbed metabolism of the cartilage is important at the onset of OA and t h r o u g h o u t its progression. The n a t u r a l equilibrium between the synthesis of the cartilage extracellular matrix and its enzymatic degradation is disturbed, resulting in loss of matrix. This loss in hyaline cartilage matrix alters the unique biochemical characteristics necessary for normal articular function [2, 3] .
In in vitro studies, glycosaminoglycan polysulfuric acid (GAGPS) (Arteparon ~, Luitpold Pharma) inhibited the action of different hydrolases, glycosidases, and proteases (e.g. cathepsin B1 and elastase) involved in the degradation of the matrix [4] [5] [6] [7] . In animal models of OA, similar inhibitory effects were demonstrated on metalloproteinases and serine proteinases [8] . GAGPS has also shown an anabolic action on chondrocytes. Kleesiek and Greiling [9] demonstrated direct stimulation of proteoglycan synthesis by chondrocytes. Adam et al. [10] showed GAGPS stimulation of collagen synthesis by chondrocytes. One study showed that GAGPS stimulated an increase in synovial fluid viscosity, related to an increase in the amount of h y a l u r o n a t e [11] . GAGPS seems to preserve the anatomy of cartilage in animal models of OA both by macroscopic examination and histology [12] .
GAGPS has been studied in numerous clinical trials for the last 25 years. GAGPS was shown to be superior to placebo in a short-term (16-weeks) double-blinded study [13] . It was also of clinical benefit in a long-term (5-year) open study in knee OA by Rejholec and Kr~lov~ [14] , where the X-ray progression of diseases was retarded. In a doubleblind, 3-year study of hand OA, GAGPS seemed to prevent the formation of OA in initially normalappearing joints; however, it did not retard the progression of disease in interphalangeal joints that already had OA at the beginning of the study [15] .
GAGPS is structurally similar to heparin. Local hematomas are sometimes observed. Changes of systemic coagulation parameters are not demonstrated at a dose of 50 mg intra-articularly (i.a.). Also, systemic adverse drug reactions have been described (atlergically-induced disorders of platelet function with shock symptoms and tendency toward bleeding and/or thrombosis and reversible hair loss). As these adverse drug reactions seem to be dose-related, we concluded that a clinical trial should be carried out with a reduced dose of GAGPS (25 mg instead of 50 rag).
Materials and methods
The study was a l-year double-blind, randomized, placebo-controlled parallel-group study of 80 patients with OA of the knee. Normal saline was used as the placebo. The therapeutic unit contained 2 × 5 ampules, 0.5 ml each, containing either 25 mg GAGPS or normal saline. It was impossible to distinguish the ampules or the packaging of the GAGPS-containing therapeutic units from those that contained placebo; they were identified only by their randomization numbers.
•
CRITERIA FOR INCLUSION INTO THE STUDY
Age of 40-75 years, and a diagnosis of symptomatic knee OA defined in accordance with the ACR criteria [16] . Duration of disease, height, weight, employment status, laterality of the more symptomatic knee, and baseline consumption of nonsteroidal anti-inflammatory drugs were determined at enrolment. In addition, patients underwent radiographic examination of both knees. EXCLUSION 
CRITERIA
These included the following: allergy to GAGPS or to heparin and heparinoids; a history of thromboembolic disease, hypertension, or coagulation disturbances; concomitant therapy with drugs known to effect blood coagulation or platelet function; type I diabetes; history of peptic or intestinal ulcer disease; hepatic, renal, or pancreatic insufficiency; and serious ischemic heart disease. Inflammatory articular diseases, synovial chondromatosis, chondrocalcinosis, gout and psoriasis; joint effusions of greater than 25 ml; obesity beyond 30% of ideal body mass, pronounced genua vara or valga; hip OA and prior lower extremity total joint replacement; prior intra-articular administration of corticosteroids or chondroprotective drugs within 3 months; infectious diseases, fever; skin disease at the site of administration; pregnancy and nursing; general contraindications to oral ibuprofen; rheumatoid factor of above 1:40, erythrocyte sedimentation rate (ESR) of above 40 mm/h, uric acid of above 500 umol/1, and platelet count less than 130,000/mm 3.
THE THERAPY
The patients received five injections of GAGPS into the more symptomatic knee joint at l-week intervals at a dose of 25 mg (i.e. one-half of the commercial GAGPS dose at doubled injection intervals). The intra-articular injections were administered by a blinded physician after clinical examination. Six patients had started a second injection cycle and had received one or more additional injections. Both GAGPS and saline were in identical vials.
THE CONCOMITANT THERAPY
Ibuprofen tablets (400mg) administered on demand up to six tablets daily, consumption monitored as one of the criteria of efficacy. Other analgesics and intra-articular steroids were not permitted.
INTERVALS OF ASSESSMENT
Before the initiation of therapy and during treatment at l-week intervals (weeks 1~6), and then at l-month intervals (weeks 10, 14, 18,~21, 26).
Primary efficacy parameter
The primary efficacy parameter was the Lequesne index of severity for the knee (ISK) [17] . The reference joint was the injected knee.
Secondary efficacy parameters
Pain score according to Jegek [18] . This evaluated seven pain qualities within a four-point scale (0: no pain, 1: slight pain, 2: medium pain, 3: severe pain, 4: unbearable pain): at the onset of walking, pain during walking, pain when walking downstairs and upstairs, pain during the night, pain during maximal flexion, and pain upon palpation. The maximum score was 28.
The visual analog scale. This was for measuring average global pain during the previous week--a horizontal scale, 100 mm, without dividing marks, measured in mm.
Functional test. This was the time in seconds to walk a distance of 20 m as fast as possible on an even surface.
Physical examination. This involved looking for any tenderness, swelling, effusion, elevated skin temperature at the knee joint, extent of mobility, Ibuprofen consumption in the course of the therapy. Number of 400 mg taken, with a maximum of 6 tablets daily.
Patients were questioned carefully for adverse events. None were suggested to the patients. All adverse events were recorded, even those thought not to be drug-related.
LABORATORY FINDINGS
Laboratory studies were determined at baseline, and at 6 and 26 weeks. The following laboratory investigations-were performed: ESR, C reactive protein, complete blood count (including platelet count and differential), serum potassium, sodium, glucose, blood, urea nitrogen, creatinine, bilirubin,
STATISTICS
Statistical evaluation was carried out in the Biometrics Department of the sponsor. Confirmatory analysis was based on testing for group differences upon the main parameter (the ISK score) at weeks 14, 18 and 22 by multivariate T<test, followed by univariate t-tests at a multiple level of ~ =5%
(closed test principle). Analysis on secondary parameters (t-test, Wilcoxon test) were done in an exploratory sense. Thus P-values reported are to be interpreted in the sense of statistical evidence for group differences.
Sample size calculation was based on the following assumptions: type I error probability = 5%, type II error probability fl = 10%, standardized difference for main parameter ISK score = 0.75. Thus 40 patients per group would be necessary to get significant statistical results (based on two-sided t-test).
Randomization was based on a code produced by a random number generator (Proc Plan, SAS (K)) according to chronological entry to the study.
Results

THE HOMOGENEITY OF THE GROUPS TREATED
Nine patients were eliminated in the statistical evaluation of the study, having not fulfilled the conditions of the protocol. Five were subsequently determined to be over the weight limit, two had taken other therapy excluded by the criteria of the study, and two did not appear for clinical followup. Thus, a total of 71 patients were evaluated: GAGPS 36; saline 35. There were no differences between the groups in any of the patient characteristics at enrollment noted in Methods, the degree of joint space narrowing medially and laterally, the baseline severity of the disease according to the Lequesne index [19] , and the baseline consumption of nonsteroid anti-inflammatory drugs (Tables I & II) .
All patients were in stage II or IiI according to Kellgren-Lawrence [20] . All patient were ambulatory. None had flexion contractures of the knees. Evidence of inflammation was present in the knees of some patients, but the presence of a large effusion was an exclusion criterion. Patients with concomitant hip OA were excluded from the study, but some had hand OA. 
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INDEX OF SEVERITY FOR THE KNEE (ISK--LEQUESNE)
This decreased after therapy with i.a. GAGPS as well as after i.a. saline when compared to baseline. The lowest values were achieved for GAGPS at 14 weeks. Significant improvement, however, persisted for the entire period of follow-up (26 weeks) after i.a. GAGPS as well as i.a. saline therapy with no significant differences between the two. The relative percentile changes in the study parameters between GAGPS and saline therapy approached significance at 14 weeks (P = 0.06). (Table III ; Fig. 1) .
A calculationbased on the study results (treatment difference ISK at week 14: 16%; estimated standard deviation: 36%) showed that the actual power of the study for statistically verifying this difference was only 47% and thus below the anticipated 90%.
VISUAL ANALOG PAIN SCALE
The results after GAGPS were better than those after saline but the differences were not significant at all assessment points (Table IV; Fig. 2 ).
JEZEK'S PAIN INDEX
There was a decrease in this index after therapy with GAGPS as well as saline. At 6 weeks the difference between GAGPS and saline was barely significant (P = 0.047) (Table V; Fig. 3 ).
There was no change in the 20 m walking time and no differences were observed between GAGPS and saline. 
IBUPROFEN CONSUMPTION
After 10 weeks of therapy this was reduced after GAGPS as well as saline. Before therapy with GAGPS, 80% of patients used three tablets or more daily; after 10 weeks, this reduced to only 43°//0 of patients. In the i.a. saline therapy group, ibuprofen consumption was 83°//0 at baseline and 47%/o at 10 weeks. There was no difference between GAGPS and saline-treated groups.
PHYSICIANS' GLOBAL ASSESSMENT
Immediately after therapy (6th week), more 'very good' results were observed after GAGPS (43%) than after saline (17%) (Fig. 4) , suggesting a therapeutic benefit of GAGPS. However, when combining 'very good' and 'good' results, the difference between them is not significant (P =0.08). Subsequent evaluations between GAGPS and saline groups were essentially the same.
PATIENTS' ASSESSMENT OF TREATMENT EFFICACY
Similarly immediately after therapy in the GAGPS group treatment efficacy was rated as 'very good' in 49~/o of cases 25% in the placebo group (Fig. 5) . These results were not statistically different (P = 0.18). The subsequent evaluations were the same as that of the physician's evaluation.
At the 6 month evaluation, complaints had completely disappeared in three patients after GAGPS and in one patient after saline placebo treatment. All analysis is based on the intent to treat principle (all randomized patients gave similar results).
with placebo, 83% reported tolerance as very good and 17% as good; no patient reported it as poor. The differences were not statistically significant. disappeared in 24 h. The remaining adverse events occurred in association with GAGPS administration: in one man, bleeding was observed for 7min from the site of injection after i.a. GAGPS ~" administration; no bleeding occurred after further injections. In another man, there was an effusion 2 days after GAGPS injection, which disappeared two days later, permitting the continuation of therapy. One woman felt local pain after GAGPS injection, which disappeared within 24h. These trivial complications, probably attributable to GAGPS injection, represented 7.5% of the cases and they never resulted in interrupting the therapy (Table VI) .
Discussion
Interpretation of the results of the study is problematic. Injection of 5 x 25mg GAGPS into the knee joint was statistically different from saline only at week 6 of the 26-week study (measured on the Pain index). The Lequesne Index tended toward a difference favoring GAGPS (P=0.06) at week 10. The other measured parameters (pain on VAS, morning stiffness, global assessment by patient and physician) also favored GAGPS but not to the level of statistical significance. From the standpoint of the biologist-physician, however, further interpretations may be made. The decrease in pain after GAGPS is considerable, almost as much as 50% of the initial values. A total of almost 50% considered the results of the therapy as very good (week 6). The differences when compared to placebo are at the limit of significance (P = 0.08). It is, however, known that the placebo effect of i.a. injections is rather high. In addition, in this case, we have a so-called untrue placebo effect, since the administration of any physiologic fluid alleviates pain. It is suggested this is due to the dilution of the enzymatic systems and inflammatory mediators present in the joint.
Ibuprofen consumption decreased rapidly in both groups, with no significant changes between GAGPS and saline. This reflects variability of the disease and its therapeutic responses as well as the need for controlled trials.
Although GAGPS was not statistically different from placebo in most measures:in this double-blind, placebo-controlled trial, a potential role for GAGPS as a symptomatic drug for OA may still exist.
The present study was initiated in 1991. Its original duration was to be 12 months with two courses of i.a. GAGPS. In the course of the study the manufacturer placed a stop to further GAGPS administration, so that the second series of injections was not performed. Nevertheless the first half of the study (6 months) was carried out in accordance with the protocol reported above.
In future we suggest that trials of GAGPS should include: (1) 50mg and 25mg i.a. GAGPS in two treatment courses of 5-10 injections each, given within one year, to establish a 'minimal effective dose' and toxicity profile; (2) a double-blind comparison study of GAGPS and other disease modifying OA drugs; (3) the use of some newer objective measures of response, such as magnetic resonance imaging or ultrasound.
